• Anza Capital portfolio company Impulse Biomedical accepted into Maryland Global Gateway Soft Landing Program, supporting planned US market entry.
• Impulse Biomedical took up residency at medtech manufacturing accelerator LaunchPort in Baltimore earlier in 2026, targeting local operations buildout.
• Work program includes regulatory engagement, technology transfer, manufacturing setup, sterilization capability development at LaunchPort.
• Company developing ZiBiPen reloadable epinephrine autoinjector, Easy Squeezy asthma assist device; reported more than 22,000 units sold.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anza Capital published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.